AIM ImmunoTech raises $4.2 million through warrant exercise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 8, 2026 8:40 AM EDTOCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM: AIM) (AIM ImmunoTech or the Company), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the Existing Warrants) to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other... More
